Monsanto obtains non-exclusive license from the Broad Institute

Jeff Akst 27 September 2016

In the latest CRISPR/Cas9 licensing agreement, Monsanto has acquired a non-exclusive world-wide license from the Broad Institute.  Monsanto plans to use CRISPR for “site-directed integration of specific genes as well as the opportunity to enhance beneficial [plant characteristics] or remove undesired plant characteristics.”

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply